Role of Direct Oral Anticoagulation Agents as Thromboprophylaxis in Antiphospholipid Syndrome
| Autor: | Sharan Jhaveri, Shilpa Samayam, Shreya Arora, Chaithanya Avanthika, Shaalina Nair, Maanya R Katta, Pahel Agarwal, Rishab Prabhu |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Thrombotic microangiopathy medicine.drug_class hypercoagulable state Rheumatology Antiphospholipid syndrome medicine Internal Medicine Intensive care medicine thrombosis Aspirin Rivaroxaban business.industry Anticoagulant General Engineering Warfarin Hydroxychloroquine Hematology medicine.disease Thrombosis antiphospholipid antibody (apla) rheumatology & autoimmune diseases direct acting oral anticoagulant thromboprophylaxis business medicine.drug |
| Zdroj: | Cureus |
| ISSN: | 2168-8184 |
| Popis: | Antiphospholipid syndrome (APS) is an autoimmune disorder that causes venous, arterial and small-vessel thrombosis, pregnancy loss, and premature birth. Cardiac valvular disease, renal thrombotic microangiopathy, thrombocytopenia, hemolytic anemia, and cognitive impairment are some of its other clinical symptoms. Antiphospholipid antibodies cause endothelial cells, monocytes, and platelets to become activated, as well as an increase in tissue factor and thromboxane A2. Complement activation might play a key function in pathogenesis. Long-term oral anticoagulation is used to treat thrombosis, and individuals having arterial episodes should be treated quickly. Patients with systemic lupus erythematosus (SLE), as well as those with solely obstetric antiphospholipid syndrome, should get primary thromboprophylaxis. Obstetric care is based on a combination of medical and obstetric high-risk management, as well as aspirin and heparin therapy. Possible supplementary therapy for this condition is hydroxychloroquine. Statins, rituximab, and novel anticoagulant medicines are all potential future treatments for non-pregnant individuals with antiphospholipid syndrome. We aim to review the role of direct-acting oral anticoagulants (DOACs) as thromboprophylactic drugs in the treatment of APS in this article. The treatment of venous thromboembolism has been transformed by a new class of DOACs. These drugs, such as rivaroxaban, function by inhibiting factor Xa directly. Not only do they have known anticoagulant actions, but they also obviate the need for dosage monitoring and modification, in contrast to warfarin. We conducted an exhaustive literature search of PubMed/MEDLINE and Google Scholar Indexes using the keywords "Antiphospholipid syndrome," "thromboprophylaxis," and "oral anticoagulants" up to September 2021. We found that DOACs have been shown to be non-inferior to warfarin in a variety of anticoagulation situations in a number of high-powered clinical studies. In many hypercoagulable conditions such as APS, DOACs are quickly establishing themselves as first-line therapy. This article is focused on comprehensively reviewing the mechanism of action of DOACs, their role as thromboprophylactic drugs, risks and complications of DOACs, and comparing their efficacy with the standard treatment protocol and warfarin. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|